argenex (NASDAQ:ARGX) Stock Price Expected to Rise, Wedbush Analyst Says

argenex (NASDAQ:ARGX) had its price objective upped by Wedbush from $1,000.00 to $1,050.00 in a note issued to investors on Tuesday,Benzinga reports. The firm currently has an “outperform” rating on the stock. Wedbush’s price target would indicate a potential upside of 18.13% from the company’s current price.

A number of other equities analysts have also issued reports on ARGX. Morgan Stanley increased their price target on argenex from $1,170.00 to $1,180.00 and gave the company an “overweight” rating in a research note on Wednesday, June 24th. Wells Fargo & Company upped their price objective on argenex from $1,260.00 to $1,291.00 and gave the company an “overweight” rating in a report on Monday, June 1st. Robert W. Baird lifted their target price on argenex from $867.00 to $932.00 and gave the stock a “neutral” rating in a report on Monday. HC Wainwright reiterated a “buy” rating and issued a $940.00 price target on shares of argenex in a research report on Thursday, June 25th. Finally, Weiss Ratings downgraded shares of argenex from a “hold (c+)” rating to a “hold (c)” rating in a report on Thursday. Two research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, argenex has an average rating of “Moderate Buy” and an average price target of $1,056.89.

argenex Trading Down 3.2%

argenex stock opened at $888.82 on Tuesday. argenex has a 52 week low of $590.78 and a 52 week high of $953.58. The stock has a market cap of $55.60 billion, a price-to-earnings ratio of 34.13, a PEG ratio of 1.21 and a beta of 0.45. The company’s 50-day moving average price is $870.53 and its two-hundred day moving average price is $815.82.

argenex (NASDAQ:ARGX) last posted its quarterly earnings data on Tuesday, July 21st. The company reported $7.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.86 by $1.46. argenex had a net margin of 32.19% and a return on equity of 43.59%. The business had revenue of $1.54 billion during the quarter, compared to analysts’ expectations of $1.45 billion. Research analysts expect that argenex will post 26.95 earnings per share for the current fiscal year.

Institutional Trading of argenex

Hedge funds have recently bought and sold shares of the company. AQR Capital Management LLC boosted its holdings in shares of argenex by 32.1% in the first quarter. AQR Capital Management LLC now owns 502 shares of the company’s stock worth $297,000 after buying an additional 122 shares during the period. NewEdge Advisors LLC lifted its position in shares of argenex by 5,962.5% in the 1st quarter. NewEdge Advisors LLC now owns 1,455 shares of the company’s stock valued at $862,000 after acquiring an additional 1,431 shares in the last quarter. Focus Partners Wealth lifted its position in shares of argenex by 22.3% in the 1st quarter. Focus Partners Wealth now owns 400 shares of the company’s stock valued at $237,000 after acquiring an additional 73 shares in the last quarter. Geneos Wealth Management Inc. boosted its stake in argenex by 550.0% in the 1st quarter. Geneos Wealth Management Inc. now owns 117 shares of the company’s stock worth $69,000 after purchasing an additional 99 shares during the period. Finally, Northwestern Mutual Wealth Management Co. boosted its stake in argenex by 60.2% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 133 shares of the company’s stock worth $73,000 after purchasing an additional 50 shares during the period. 60.32% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting argenex

Here are the key news stories impacting argenex this week:

• Positive Sentiment: argenx agreed to acquire Forte Biosciences (NASDAQ:FBRX) for approximately $2.2 billion, or $77 per share in cash—a 41% premium to Forte’s prior closing price. The transaction adds FB102, an experimental anti-CD122 antibody, to argenx’s immunology pipeline. Positive Phase 1b data in vitiligo and celiac disease support the potential for FB102 to become a “pipeline-in-a-product” asset addressing diseases with significant unmet need. argenx to Acquire Forte Biosciences, Adding FB102 to Its Immunology Pipeline
• Positive Sentiment: HC Wainwright raised its EPS forecasts for argenx’s fiscal 2026 through 2030, including increases to $34.38 for 2027, $43.50 for 2028, $53.47 for 2029 and $64.39 for 2030. The upgrades indicate stronger expected long-term earnings growth and maintain a Buy rating with a $940 price target. HC Wainwright Analysts Raise Earnings Estimates for argenx
• Neutral Sentiment: HC Wainwright modestly reduced its fourth-quarter 2026 EPS estimate to $6.93 from $7.00, despite raising the full-year 2026 forecast to $26.27 from $24.35. This creates a mixed near-term earnings signal but leaves the broader outlook favorable.
• Neutral Sentiment: Robert W. Baird lifted its price target to $932 from $867 but retained a Neutral rating, suggesting limited conviction that valuation will materially outperform despite the higher target. Benzinga
• Negative Sentiment: The $2.2 billion all-cash Forte acquisition will require substantial capital and carries clinical, regulatory and integration risk. Investors may remain cautious until FB102 demonstrates additional efficacy and advances successfully through later-stage trials. argenx to Buy Forte Biosciences for About $2.2 Billion

argenex Company Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.